Y-Intercept (HK)
GLUE icon

Y-Intercept (HK)’s Monte Rosa Therapeutics GLUE Stock Holding History

Y-Intercept (HK)’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.75M Buy
230,321
+205,172
+816% +$3.52M 0.06% 470
2026
Q2 		$609K Buy
+25,149
New +$475K 0.01% 1252

Other funds holding GLUE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Wealth Effects
Wealth Effects Boston, Massachusetts $370M AUM 63.53% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Paladin Partners
Paladin Partners Hartland, Wisconsin $162M AUM 13.31% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Y-Intercept (HK)'s GLUE Position: Q3 2026 in Review

Y-Intercept (HK) increased its Monte Rosa Therapeutics (GLUE) stake by 816% in Q3 2026, buying an estimated $3.52M and bringing the position to 230,321 shares worth $2.75M. The position accounts for 0.06% of the portfolio, ranked #470.

Y-Intercept (HK) first reported a position in GLUE in Q2 2026 and has held it in 2 quarters since. 17 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • Y-Intercept (HK) held 230,321 shares of Monte Rosa Therapeutics worth $2.75M as of Q3 2026.
  • Y-Intercept (HK) bought 205,172 Monte Rosa Therapeutics shares in Q3 2026, an estimated $3.52M.
  • Monte Rosa Therapeutics made up 0.06% of Y-Intercept (HK)'s portfolio in Q3 2026, its #470 holding.
  • Y-Intercept (HK) first reported a position in Monte Rosa Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 17 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.